Niagen Bioscience, Inc.

NAGE Nasdaq SEC CIK 1386570
Follow Niagen Bioscience Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $27.2M −20% vs same quarter last year
Net income −$1.2M −125.6% vs same quarter last year
EPS, diluted −$0.01 −120% vs same quarter last year
Operating cash flow $2.6M −28.9% vs same quarter last year
Revenue by quarter
$29.1M
$30.5M
$31.1M
$34M
$33.8M
$31.5M
$29.8M
$27.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100M$150MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$129.4M$17.4M
FY24$99.6M$8.6M
FY23$83.6M−$4.9M
FY22$72.1M−$16.5M
FY21$67.4M−$27.1M
FY20$59.3M−$19.9M
FY19$46.3M−$32.1M
FY18$31.6M−$33.3M
FY17$21.2M−$11.4M
FY16$21.7M−$2.9M
FY15$17.9M−$2.8M
FY14$15.3M−$5.4M
FY13$10.2M−$4.4M
FY12$11.6M−$11.7M
FY11$8.1M−$7.9M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−150%−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2564.3%12.6%13.4%
FY2461.8%7.8%8.6%
FY2360.8%−6.7%−5.9%
FY2259.4%−25.9%−23%
FY2161.5%−40.1%−40.2%
FY2059.5%−33.5%−33.6%
FY1955.7%−67.6%−69.4%
FY1850.9%−105.1%−105.6%
FY1749.4%−77.2%−53.7%
FY1648%−13.4%−13.5%
FY1542.1%−11.6%−15.5%
FY1434.8%−34.2%−35.2%
FY1330.8%−43.2%−43.5%
FY1219.6%−100.2%−100.4%
FY1130.5%−96.9%−97.3%
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21-
FY20-
FY19−$21.2M
FY18−$22.2M
FY17−$11M
FY16−$4.4M
FY15−$2.6M
FY14−$2.7M
FY13−$4M
FY12−$10.1M
FY11−$4.2M
Returned to shareholdersDividends paid and shares bought back
$0$200K$400K$600KFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$251K
FY24$0
FY23-
FY22-
FY21-
FY20-
FY19-
FY18$404K
FY17$0
FY16-
FY15-
FY14-
FY13-
FY12$8.2K
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Niagen Bioscience
  • Healthcare median
−150%−100%−50%0%50%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNiagen BioscienceHealthcare median
FY2513.4%−30.6%
FY248.6%−47%
FY23−5.9%−58%
FY22−23%−80.4%
FY21−40.2%−71.8%
FY20−33.6%−62.2%
FY19−69.4%−46.2%
FY18−105.6%−49.6%
FY17−53.7%−45.9%
FY16−13.5%−36%
FY15−15.5%−37.8%
FY14−35.2%−35.5%
FY13−43.5%−37.1%
FY12−100.4%−29.1%
FY11−97.3%−27.9%